T-Cell Lymphoma Clinical Trials

A listing of T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 181 clinical trials
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma Nasal Type

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

renal function
  • 0 views
  • 26 Jan, 2021
  • 1 location
VP-16 Ifosfamide Dexamethasone L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

patients with stage III/IV extranodal NK/T-cell Lymphoma.

dexamethasone
etoposide
ejection fraction
neutrophil count
platelet count
  • 6 views
  • 26 Jan, 2021
  • 1 location
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma

measurable disease
refractory t-cell non-hodgkin lymphoma
tyrosine
t-cell lymphoma
  • 15 views
  • 25 Jan, 2021
  • 19 locations
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

, interventional, single arm, open label, treatment study to evaluate the safety, tolerability and efficacy of HSP-CAR30 in patients with relapsed/refractory Hodgkin lymphoma and relapsed/refractory T-cell

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

This study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the previous

cell transplantation
adult t-cell leukemia/lymphoma
hodgkin's disease
ct scan
platelet count
  • 23 views
  • 19 Feb, 2021
  • 5 locations
A Phase 1 Study of Romidepsin CC-486 (5-azacitidine) Dexamethasone and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

-positive cutaneous T-cell lymphoma Age greater than or equal to 18 years of age ECOG performance status of less than or equal to 2 (or less than or equal to 3 if decrease is due to

  • 0 views
  • 13 Feb, 2021
  • 1 location
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia

This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia

lymphoid leukemia
ejection fraction
lymphoblastic lymphoma
oximetry
lymphoma
  • 2 views
  • 26 Jan, 2021
  • 1 location
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

For participants with CD30 positive Mature T-cell lymphomas who have received brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A-CHP) as induction (4 to 6 cycles) and achieved complete response (CR) or chemo-sensitive partial response (PR) and deemed suitable for autologous stem cell transplant (ASCT) as consolidation, the investigators propose to add …

adult t-cell leukemia/lymphoma
ct scan
doxorubicin
brentuximab
chop regimen
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.

diffuse large b-cell lymphoma
large b-cell lymphoma
cancer
b-cell lymphoma
  • 0 views
  • 16 Feb, 2021
  • 6 locations
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

, peripheral T-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma not otherwise specified, primary mediastinal B-cell lymphoma, grey zone lymphoma, enteropathyassociated T-cell lymphoma, or

fludarabine
anti-cd20 monoclonal antibody
ct scan
remission
platelet count
  • 1 views
  • 27 Jan, 2021
  • 1 location